MDL 63246

Drug Profile

MDL 63246

Alternative Names: RA A 1

Latest Information Update: 30 Sep 2005

Price : $50

At a glance

  • Originator Biosearch Italia
  • Class Antibacterials; Glycopeptides; Peptide antibiotics
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Bacterial infections

Most Recent Events

  • 30 Sep 2005 Vicuron Pharmaceuticals has since been acquired by and merged into Pfizer
  • 08 Jun 2001 No-Development-Reported for Bacterial infections in Italy (Unknown route)
  • 14 Jul 1998 Preclinical development for Bacterial infections in Italy (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top